Ascentage Pharma Group International (FRA:36X) 3-Year EBITDA Growth Rate : 39.50% (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Ascentage Pharma Group International 3-Year EBITDA Growth Rate?

Ascentage Pharma Group International's EBITDA per Share for the six months ended in Dec. 2024 was €-0.22.

During the past 3 years, the average EBITDA Per Share Growth Rate was 39.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 34.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ascentage Pharma Group International was 39.50% per year. The lowest was -191.60% per year. And the median was -13.40% per year.

Competitive Comparison of Ascentage Pharma Group International's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Ascentage Pharma Group International's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascentage Pharma Group International's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Ascentage Pharma Group International's 3-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

Ascentage Pharma Group International 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Ascentage Pharma Group International (FRA:36X) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Ascentage Pharma Group International 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Ascentage Pharma Group International's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascentage Pharma Group International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (FRA:36X) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

AAPG:USA 06855:Hong Kong 36X0:Germany 36X0:Germany 36X:Germany

Address

68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000

Website

https://www.ascentagepharma.com

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.

Ascentage Pharma Group International Headlines

No Headlines